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SYSTEMIC PHARMACOKINETICS AND CARBONIC ANHYDRASE INHIBITION 
OF DORZOIAMIDE 
Adamsom I, Ccmor I, Stmhmaier K, Tan&a W, Constanrer M, Kusma S, Winchell G 
Merck Research Labs, Blue Bell, PA, USA 
fir-pose: Dorzolamide @ORE) is a topical carbonic anhydrase (CA) inhibitor that is 
approved for treatment of open-angle glauccma and ocular hypertension. DORE exerts 
its effects directly in the eye at substantially lower doses and therefore with less systemic 
exposure than oral CA inhibitors To evaluate DORZ’s potential for systemic CA 
inhibition, maximum systemic exposure was simulated through oral dosing in healthy 
subjects and rotally impaired patients. 
Methods: In one study, 8 healthy subjects received 2 mg DORZ pe, b.i.d. for 20 wks 
and in a separate study 9 subjects with mild to moderate renal impairment (creatininc 
clearance: 30-60 ml/min/1.73 m2) received the same dose for 24 wks. The oral route was 
chosen to reduce the dosing variability associated with topical ocular administration; the 
dose appmximstes the maxhnnm total systemic exposure possible from a daily dose of 
2% DORZ, one drop OU t.i.d. Whole blood. plasma, and urine samples were collected 
weekly for the first I2 wks and biweekly thereafter in the healthy subject stndy and were 
collected biweekly after the first week in the renally impaired study. Both studies 
measured drug and Ndcscthyl metabolite ccnccntmtions in the RBCs, plasma, end urine; 
CA-iscenzyme II and total CA activity in RBCs; and clinical biochemical parameters in 
RBCs and urine. 
Results: DORZ and mctabclite accumulated in RBCs as a result of binding to 
intracellular CA. Steady-state levels of DOAZ were reached at 4 wks for drug and within 
13-14 wks for metabolite in both studies. Plasma concentrations of DORZ and metabclite 
were generally below the level of dctcction ( I5 nM) in healthy and <lOOnM in rettally 
impaired subjects. Although steady-state levsls of DORZ and, particularly, metabolite 
were higher in rcnally impaired patients, steady-state inhibition of CA-II was similar in 
both studies: 94-96% in healthy subjects r&95-96% in renally impaired patients, as was 
steady-state inhibition oftotal CA: El-88% in healthy and 77-84% in rettally impaired 
subjects. No clinically hnpottant bic&mical changes were observed in either study 
Conclusions: Steady-state inhibition in both studies was below the levels anticipated to 
be necessary to affect renal function (i.e. >99% CA-II inhibition) or respiration (i.e. at 
least 96% total CA inhibition). Therefore, topical use of DORZ in healthy subjects and 
moderately renally impaired patients is not expected to canse the marked biochemical 
changes which can occur with oral CA inhibitors. 
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CONGENITAL MICROCORIA: ASSOCIATION WITH MYOPIA 
AND GLAUCOMA. 
TOULEMONT PJ’ , URVOY M’ , COSCAS G=, LE CALLONNEC AI 
and CUVILLIERS AFl. 
IDep. of Ophthalmol., Rennes I University (Fr.). 
2Dep. of Ophthalmol., University Eye Clinic Creteil (Fr.) 
Puroose; Congenital microcoria, a bilateral condition of the 
iris dilatator, is defined as a pupil with a diameter of less 
than 2 mm when looking at a distant object. Although it is 
usually a hereditary condition resulting from autosomal 
dominant transmission with no marked difference between 
the sexes, it is sometimes sporadic. The ocular abnormalities 
associated with this condition (myopia, astigmatism and 
glaucoma) have never been linked to the malformation. 
Methods: 42 members of a family were examined: 23 
members with microcoria and 19 without. the two groups 
were studied to identify symptoms of the condition and its 
associated abnormalities. 
Results; There was a very strong correlation between 
microcoria and myopia (Fisher’s exact test: p<O.OOOOl) , 
between microcoria and astigmatism (Fisher’s exact test: 
p<O.OOOl) and between microcoria and glaucoma (Fisher’s 
exact test: p=O.Oll). 
Bs: There is a statistical correlation between 
myopia, glaucoma and microcoria and the disorders are 
associated with the condition in a non-fortuitous way. The 
functional prognosis for microcoria appears to be poor, 
because of refractive disorders and, more particularly, a 
link between microcoria and glaucoma that is difficult to 
explain 
lDENTIFlCATION OF A NEW MUTATION CAUSING AN 
ANIRIDIA IN TEE PST DOMAIN OF PAX6. 
SAHLY I (11, ARITROL M. (l,CI, , GEAZI I. (1) RDBRAUDEAU 
F. (1) ,GERARD M. cZ),n REMANSM.@,,DUFIRRJ.L.(l) 
(1)  C!enh ,b Rshmhc ‘tM.,su~c en OphwmObfic Famdt6 dc MMccine NC&m- 
tbfmta M9bdes -  tJniveni* Paris V 
(2)  LAbDnmirc de cc~t3iq~ M0ttcubire d”  Ds”eb*mcnl- Facuttt de hid&zinc 
NcchRldanD Mdadm -  “rd”cntu Pads ”  
Purpme: PAX 6 gene is a major developmentaJ gene for the eye. 
Mutations in this gene can cause an ensemble of phendypes inchtding 
aIlhi& congenital glaucoma, CmgmitaI CatRlact, Peter’s anomaly, 
postcxim embryotoxm aud possibly rieger syndmme. Our aim is to 
screen this eeOe for mutations. 
technique for detecting v&t 
. _ 
bands corrmponding to ampl&d axons 
and direct sequencing for derecting mutatiom. 
ResuitszOur preliminary screening of the 14 exons of the PAX 6 gene 
using SSCF’ and direct sequencing allowed us to detect in an aniridia 
path an 8 base pair ins&ion in Exon 10 of PAX 6 gene. This DNA 
insertion produces a downstream stop codon and leads to the disrt@ion 
of the PST domain which is strongly suspected to be the transactivatiug 
domain of PAX 6. 
Coueluaion: The reported mutation is a severeone leading to a complete 
mitidia with congenital cataract. Aniridia is a pamxuhu generic disease. 
Mutatiotts of PAX 6 geue must be searched both in sporadic and 
inheited fbmls of atutidia. 
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EXCLUSION OF CHROMOSOME lq AS THE SUSCEPTIBILHY 
LOCUS IN FAMILIAL PRIMARY OPEN ANGLE GLAUCOMA 
BREZIN A.P.1, DUPONT de DINECHIN S.1, HAMARD P.2, 
BELMOUDEN A.1, ADAM M.1, BACH J.F.1, GARCHON H.J.1 
1INSERM U25, HBpital Necker, Paris (France) 
2CHNO des XV/XX, Paris (France) 
Purpose: Heredity is a major risk factor for primary 
open angle glaucoma (POAG). Autosomal dominant 
juvenile onset POAG has been linked to a locus (GLClA) 
on chromosome lq21-q31. The Purpose of this study is 
to characterize families with autosomal dominant POAG, 
unlinked to GLCIA. Methods: Three pedigrees were 
analyzed in this study. Criteria for POAG diagnosis 
included intraocular pressures (IOP)>22mmHg; 
characteristic optic nerve damage; visual field-defects; 
grade III-IV gonioscopy. Blood samples were obtained 
with informed consent. Genomic DNA samples were 
haplotyped with 8 microsatellite markers spanning the 
GLClA region. Results: In these 3 pedigrees, the 
median age of diagnosis was higher than in those 
families with juvenile POAG. Chromosome 1 haplotypes 
did not cosegregate with POAG, ruling out the role of 
GLClA as the susceptibility gene in these families. 
Conclusions: These data provide a basis for the study of 
genetic heterogeneity of familial POAG. Analysis of 
additional pedigrees will indicate whether a later age of 
onset is a consistent feature of chromosome 1 unlinked 
POAG. 
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